

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Please amend claims 8 and 10-14.

Please cancel claims 1, 2, 4-7 and 9.

Please add new claims 18-26.

1-7. (Canceled)

8. (Currently Amended) A method of treating a subject suffering from a ~~TNF α -related disorder, wherein the TNF α -related disorder is psoriasis, comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of administering a therapeutically effective amount of a~~ an anti-TNF α antibody, or an antigen-binding fragment thereof, that to the subject, wherein the antibody dissociates from human TNF α with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of 1×10^{-3} s $^{-1}$ or less, both determined by surface plasmon resonance, and neutralizes human TNF α cytotoxicity in a standard *in vitro* L929 assay with an IC $_{50}$ of 1×10^{-7} M or less, such that said psoriasis TNF α -related disorder is treated.

9. (Canceled)

10. (Currently Amended) A method of treating a subject suffering from a ~~TNF α -related disorder, wherein the TNF α -related disorder is psoriasis, comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of administering a therapeutically effective amount of a~~ an anti-TNF α antibody, or an antigen-binding fragment thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, such that said TNF α -related disorder psoriasis is treated.

11. (Currently Amended) The method of claim 8 or 10 ~~any one of claims 8, 9, or 10,~~ wherein the anti-TNF α antibody is D2E7, or an antigen-binding fragment thereof.

12. **(Currently Amended)** The method of claim 8 or 10 ~~any one of claims 8, 9, or 10~~, wherein the anti-TNF α antibody, or antigen-binding fragment thereof is administered with at least one additional therapeutic agent.

13. **(Currently Amended)** A method of treating a subject suffering from a ~~TNF α -related disorder, wherein the TNF α -related disorder is psoriasis~~, comprising biweekly, subcutaneous administration to the subject of a unit dosage form comprising 10-150 mg of a D2E7 antibody administering a therapeutically effective amount of D2E7, or an antigen binding fragment thereof, such that said psoriasis ~~TNF α -related disorder~~ is treated.

14. **(Currently Amended)** The method of claim 13, wherein D2E7, or antigen binding fragment thereof, is administered with at least one additional therapeutic agent.

15-17. **(Canceled)**

18. **(New)** The method of claim 8, wherein the unit dosage form comprises 20-80 mg of the human anti-TNF α antibody, or antigen-binding fragment thereof.

19. **(New)** The method of claim 10, wherein the unit dosage form comprises 20-80 mg of the human anti-TNF α antibody, or antigen-binding fragment thereof.

20. **(New)** The method of claim 11, wherein the unit dosage form comprises 20-80 mg of D2E7, or antigen-binding fragment thereof.

21. **(New)** The method of claim 11, wherein the unit dosage form comprises 20-80 mg of D2E7.

22. **(New)** The method of claim 8, wherein the unit dosage form comprises about 40 mg of the human anti-TNF α antibody, or antigen-binding fragment thereof.

23. (New) The method of claim 10, wherein the unit dosage form comprises about 40 mg of the human anti-TNF α antibody, or antigen-binding fragment thereof.
24. (New) The method of claim 11, wherein the unit dosage form comprises about 40 mg of D2E7, or antigen-binding fragment thereof.
25. (New) The method of claim 11, wherein the unit dosage form comprises about 40 mg of D2E7.
26. (New) The method of claim 12, wherein the additional therapeutic agent is selected from the group consisting of a topical corticosteroid, a vitamin D analog and a topical or oral retinoid.